Saunders, Mark P
AffiliationMedical Oncology, Mayo Clinic, Rochester, MN
MetadataShow full item record
AbstractSince 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.
CitationDuration of adjuvant chemotherapy for stage III colon cancer. 2018, 378(13): 1177-1188 N Engl J Med
JournalThe New England Journal of Medicine